Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3K3A-APC in Acute Ischemic Stroke
NCT05484154Phase 3Withdrawn
- Sponsor
- ZZ Biotech
- Start
- Oct 2024
- Primary completion
- Jul 2026
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 3, randomised, double-blind trial of 3K3A-APC in acute ischemic stroke (AIS) (4 arms), sponsored by ZZ Biotech. Primary endpoint: Modified Rankin Scale score at 90 days. Planned start Oct 2024; status: withdrawn.
02
Drugs
3K3A-APC
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT05484154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05484154.